Table 2 Systematic review of studies on furosemide and the outcome

Badawy [16]

ADCHF

Treatment

HDF

Study group 5/20, control group 3/20; OR = 1.89 (95% CI 0.38–9.27); p = 0.43

NA

Bagshaw [17]

AKI (ICU patients)

Treatment

Saline

Study group 3/37, control group 5/36; OR = 0.55 (95% CI 0.12–2.48); p = 0.43

Study group 10/37, control group 10/36; OR = 0.96 (95% CI 0.34–2.69); p = 0.94

Barbanti [18]

CIN (post TAVI)

Prevention

Saline

Study group 1/56, control group 2/56; OR = 0.49 (95% CI 0.04–5.57); p = 0.57

NA

Bart [19]

ADCHF

Treatment

Standard of care

Study group 0/20, control group 1/20; OR = 0.32 (95% CI 0.01–8.26); p = 0.49

NA

Bart [20]

ADCHF

Treatment

UF

Study group 13/94, control group 16/94; OR = 0.78 (95% CI 0.35–1.73); p = 0.54

NA

Berthelsen [21]

AKI (ICU patients with fluid overload)

Treatment

Furosemide + CRRT

Study group 6/13, control group 2/7; OR = 2.14 (95% CI 0.3–15.36); p = 0.45

NA

Briguori [22]

CIN (CKD patients)

Prevention

Bicarbonate + NAC

NA

Study group 1/146, control group 6/146; OR = 0.16 (95% CI 0.19–1.35); p = 0.09

Cantarovich [8]

AKI (ICU + nephrology unit patients)

Treatment

Placebo

Study group 59/166, control group 50/164; OR = 1.26 (95% CI 0.79–1.99); p = 0.33

NA

Costanzo [23]

ADCHF

Treatment

UF

Study group 11/100, control group 9/100; OR = 1.25 (95% CI 0.5–3.14); p = 0.64

NA

Costanzo [24]

ADCHF

Treatment

UF

Study group 11/95, control group 9/94; OR = 1.24 (95% CI 0.49–3.14); p = 0.65

NA

Costanzo [25]

ADCHF

Treatment

UF

Study group 1/114, control group 2/110; OR = 0.48 (95% CI 0.04–5.35); p = 0.55

NA

Dussol [26]

CIN (CKD patients)

Prevention

Saline

NA

Study group 0/29, control group 0/30; OR = 1.03 (95% CI 0.2–53.83); p = 0.99

Grams [27]

AKI (ALI)

Treatment

Low-dose furosemide

Study group 64/169, control group 56/137; OR = 0.73 (95% CI 0.42–1.26); p = 0.26

Study group 45/169, control group 44/137; OR = 0.77 (95% CI 0.47–1.26); p = 0.29

Hanna [28]

ADCHF

Treatment

UF

Study group 4/17, control group 4/19; OR = 1.15 (95% CI 0.24–5.56); p = 0.86)

NA

Lassnigg [7]

AKI (post cardiac surgery)

Prevention

Saline

Study group 4/41, control group 1/40; OR = 4.22 (95% CI 0.45–39.5); p = 0.21

Study group 2/41, control group 0/40; OR = 5.13 (95% CI 0.24–110.2); p = 0.29

Lim [29]

AKI (post cardiac surgery)

Prevention

Placebo

Study group 0/40, control group 0/39; OR = 0.98 (95% CI 0.19–50.4); p = 0.99

NA

Mahesh [30]

AKI (post cardiac surgery)

Prevention

Saline

Study group 1/21, control group 2/21; OR = 0.47 (95% CI 0.04–5.68); p = 0.56

Study group 1/21, control group 0/21; OR = 3.15 (95% CI 0.12–81.74); p = 0.49

Marenzi [31]

CIN (CKD patients)

Prevention

Saline

Study group 1/87, control group 3/83; OR = 0.31 (95% CI 0.03–3.04); p = 0.31

Study group 1/87, control group 3/83; OR = 0.31 (95% CI 0.03–3.04); p = 0.31

Marenzi [32]

CHF

Treatment

UF

Study group 11/29, control group 7/27 OR = 1.75 (95% CI 0.56–5.45); p = 0.34;

NA

van der Voort [33]

AKI (ICU patients post CVVHF)

Treatment

Placebo

Study group 4/36, control group 4/35; OR = 0.97 (95% CI 0.22–4.22); p = 0.96

Study group 13/36, control group 7/35; OR = 2.26 (95% CI 0.77–6.6); p = 0.14